Content area
Full text
Merck Serono, a division of Merck, Darmstadt, Germany, announced today that it will increase its commitment to its strategic corporate venture capital fund MS Ventures to 100 million. MS Ventures was originally established in March 2009 with a 40 million commitment to invest in emerging biotechnology companies.
Since its foundation, MS Ventures has become an important component of Merck Serono s window to companies receiving funding through venture capital and developing next generation platforms and products. Today s prolonged and...